Supplemental Table 2 . Yeast strains used in this study Supplemental M. Fitting of data to a simple 1:1 binding model was unsuccessful, therefore a 'heterogenous ligand' model was fit to the curves using Biacore evaluation software. The black lines correspond to the quality of fit against the experimental data (colors). The small spike upon dissociation (180 second time point) is likely due to a minor buffer mismatch. (B) Binding of R1402E mutant of Myo2 to GST-Sec15. The myosin mutant was injected over a GST-Sec15 coupled CM5 chip at concentrations ranging from 0.1 M -17.5 M. The fitted data to determine the K D are shown. Pink and aquamarine points are duplicates at 3 M Myo2-R1402E. Steady state binding affinity (vertical line) was derived using Biacore evaluation software, as described in Extended Experimental Procedures. (C) vYFP-Sec15 is expressed at normal levels in myo2 mutants that are defective in binding Sec15. Indicated plasmids transformed into LWY10970 (myo2 , sec15 cells). Figure S6 , related to Figure 6 . Identification of the Myo2 binding region on Sec15. (A) Sec15 sequences were aligned using ClustalW2. Identical residues are shaded in black, similar residues are shaded in light gray. Conserved negatively charged residues among three species including yeast are indicated by asterisks. Bold black characters; amino-acids of DmSec15 in the crystal structure (Wu et al., 2005) , red characters; aminoacids of ScSec15 in the predicted crystal structure. (B) Lethal Sec15 mutants interact with each exocyst subunit tested. Sec15-D681K/E684K and -D705K mutants assemble into the exocyst complex. Indicated plasmids were expressed in a SEC10-vYFP strain (LWY8380). TAP constructs were pulled down from yeast lysates via IgG beads and bound proteins analyzed by immunoblot with antibodies directed against Sec15, GFP, Sec6, Exo84 and Pgk1 (loading control). Green; conserved residue with Q1472 in Myo2. Red; conserved residues with K1444 and Q1447 in Myo2. Black residues that are not conserved with residues in the Rab GTPase or the Sec15 binding sites of Myo2. Cyan and blue; predicted She3 binding residues. Note that Myo4 residue Y1329 (cyan) corresponds spatially with Myo2-L1411, which is in the Rab binding site. MATa, ura3-52, leu2-3,-112, his3-200, trp1-901, lys2-801, suc2-9 (Catlett and Weisman, 1998) 1, 3, 6 ura3-52, leu2-3,-112, his3-200, trp1-901, lys2-801, suc2-9, myo2 ::TRP1, YCp50-MYO2 (Catlett and Weisman, 1998) 1, 2, 4, S2 MATa, 112, gal4 , gal80 , met2 ::GAL7-lacZ (James et al., 1996) 1, 5 This study 3 MATa, This study 3 MATa, This study 3 MATa, This study 3, S6
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Supplemental Experimental Procedures Yeast Strain and Media
Yeast strains used are in Supplementary Table S2 . Deletion and fusion strains were constructed as described (Longtine et al., 1998; Nagai et al., 2002) . Sec3-, Sec5-, Sec10-and Exo70-vYFP strains were made using a pBS7 plasmid (Nagai et al., 2002) . Yeast cultures were grown at 24 °C unless stated otherwise. Yeast extract-peptone-dextrose (1% yeast extract, 2% peptone, 2% dextrose; YEPD), synthetic complete (SC) lacking the appropriate supplement(s), and 5-FOA media were made as described (Kaiser, 1994) .
Unless stated otherwise, SC medium contained 2% dextrose.
Plasmids
Plasmids used are in Supplementary Table S3 .
For generation of pRS413 MYO2-vYFP N , first an NheI site was generated at the Cterminal end of MYO2 by PCR using primers (5'-CGT TCA AGA CGG CCA Cgc tag cTG ATG GCG CGA GAA AC-3') and (5'-GTT TCT CGC GCC ATC Agc tag cGT GGC CGT CTT GAA CG-3') to make pBlueScript (pBS) myo2-tail-NheI from pBS myo2-tail (pNLC15; pBS EcoRI-EcoRI fragment of myo2-tail) (Jin et al., 2009 ). The mutated nucleotides are in lower case. N-terminal half of vYFP was amplified by PCR from pBS7 plasmid (Nagai et al., 2002) using primers (5'-CAC gct agc GGT CGA CGG ATC CCC GGG TTA ATT AAC AGT AAA GGA GAA GAA CTT TTC ACT GG-3') and (5'-CAC tct aga CTA TTC AAT GTT GTG TCT AAT TTT GAA GTT AAC-3').
The N-terminal vYFP fragment was inserted into the pBS myo2-tail-NheI at the NheI site to generate pBS myo2-tail-vYFP N . A StuI-SacI fragment was subcloned from pBS myo2-tail-vYFP N into pRS413 MYO2 at the StuI and SacI sites.
For generation of pRS413 mCherry-MYO2, first, an AvrII site was generated at the Nterminus of MYO2 by PCR using primers (5'-GAT ATT ACA GCG TAT AAT GcC Tag gGA AGT GGG TAC ACG-3') and (5'-CGT GTA CCC ACT TCc ctA GgC ATT ATA CGC TGT AAT ATC-3') to make pBS AvrII-MYO2(XhoI-NotI). mCherry fragment was amplified using primers (5'-AAT cCT agg GTG AGC AAG GGC G-3') and (5'-GCG act agt CTT GTA CAG CTC GTC C-3'). The mCherry fragment was inserted into the pBS For generation of pRS415 vYFP C -SEC4, a SpeI site was generated at the N-terminus of SEC4 by PCR using primers (5'-GCC TGA act agt CAT GTT TAT CTT GTT ATG TTT ATA TTC TTT CTG G-3') and (5'-AAC ATG act agt TCA GGC TTG AGA ACT GTT TCT G-3') to make pRS415 SpeI-SEC4. The C-terminal half of vYFP was amplified from pBS7 using primers (5'-ATG gct agc GAC AAA CAA AAG AAT GGA ATC AAA GCT AAC-3') and (5'-TGA act agt gtt aat taa ccc ggg gat ccg tcg acc TTT GTA TAG TTC ATC CAT GCC-3'). The C-terminal vYFP fragment was inserted into the pRS415
SpeI-SEC4 at the SpeI site to generate pRS415 vYFP C -SEC4.
To generate pGEX4T-1 Sec4 and pGAD-C1 Sec4, the full-length SEC4 ORF was amplified using primers (5'-AAG GGA TCC ATG TCA GGC TTG AGA ACT G-3') and (5'-TTC GTC GAC TCA ACA GCA ATT TGA TTT AGA ACT G-3'). The SEC4 fragment was inserted into pGEX4T-1 or pGAD-C1 at BamHI and SalI sites. For generation of Sec4-S34N, -Q79L and N133I mutants, the SEC4 gene was mutagenized by site-directed mutagenesis using the following primers: ( For generation of pRS413 MYO2-SEC4, full-length SEC4 or sec4-SS missing the initiating methionine was amplified using primers (5'-CAA gct agc TCA GGC TTG AGA ACT GTT TCT G-3') and (5'-AGA tct aga TCA ACA GCA ATT TGA TTT AGA ACT G-3') or (5'-AGA tct aga TCA Act Gct ATT TGA TTT AGA ACT GTT TCC-3').
The SEC4 fragment was inserted into the pBS myo2-tail-NheI at the NheI site to generate pBS myo2-tail-SEC4. Finally, an EcoRI-EcoRI fragment was subcloned from pBS myo2-tail-SEC4 into pRS413 MYO2 EcoRI-EcoRI. For generation of pRS413 MYO2-YPT1, full-length YPT1 was amplified using primers (5'-AGC gct agc ATG AAT AGC GAG TAC GAT TAC C-3') and (5'-CGC tct aga TCA ACA GCA GCC CCC-3').
His-tagged Sec15, pET15b Sec15, was made by GENEART AG. Codon usage was adapted to the codon bias of E. coli genes by GeneOptimizer®,
To express GST-Sec15, full length SEC15 fragment was amplified from pET15b SEC15 using primers (5'-GGC gga tcc ATG GAT CAG GAA GGC CAG-3') and (5'-GCC gtc gac TTA TTA GCG GCG GTT AAA AAA TTT CG-3') and inserted into pGEX 4T-1 at BamHI and SalI sites to generate pGEX 4T-1 Sec15.
For generation of pRS415 SEC15 and YCp50 SEC15, a HindIII-BamHI fragment of SEC15 was subcloned into pRS415 or YCp50 at HindIII and BamHI sites.
For generation of YCp50 SEC15 / MYO2 which has both SEC15 and MYO2 genes in a single plasmid, XhoI-SmaI fragment of MYO2 from pRS413 MYO2 was subcloned into the YCp50 SEC15 at SalI and PshAI sites to generate YCp50 SEC15 / MYO2.
For generation of pRS415 SEC15-vYFP C , first an NheI site was generated at the Cterminus of SEC15 by PCR using primers, (5'-CCC gTC gAC ACC AGG TAC TAT AGA TAG TAA TG-3'), (5'-agt GGA TCC GCT AAG TCT TTC-3'), (5'-CAA ATT TTT TAA TAG ACG Tgc tAg cAT TAG ATA TTA TCT CAG TAT AAT C-3') and (5'-GAT AAT ATC TAA Tgc Tag cAC GTC TAT TAA AAA ATT TGG C-3') to generate pBS SEC15(SexAI-BamHI)-NheI. The C-terminal half of vYFP was amplified from pBS7 using primers (5'-CAC gct agc GGT CGA CGG ATC CCC GGG TTA ATT AAC GAC AAA CAA AAG AAT GGA ATC AAA GcT AAC-3') and (5'-CAC tct aga CTA TTT GTA TAG TTC ATC CAT GCC-3'). The C-terminal vYFP fragment was inserted into the pBS SEC15(SexAI-BamHI)-NheI at the NheI site to generate pBS SEC15-vYFP C . The SexAI-BamHI fragment was subcloned from pBS SEC15-vYFP C into pRS415 SEC15 at SexAI and BamHI sites.
For generation of pRS415 vYFP-SEC15, first an NheI site was generated at the Nterminus of SEC15 by PCR using primers, (5'-TGT AAA ACG ACG GCC AGT-3'), (5'-CTT GGT Cgc tag cCA TTA TTG ACA GCT AAT TCG CTA CAA C-3') (5'-GCT GTC AAT AAT Ggc tag cGA CCA AGA AGG CCA GCC-3') and (5'-ccg ctc tag aTG ATC AAT TCT TGA CAT TTG CTG G-3'), to generate pBS NheI-SEC15(HindIIIBclI). Full length of vYFP was amplified from pBS7 using primers (5'-gct agc AGT AAA GGA GAA GAA CTT TTC ACT GG-3') and (5'-ACT AGT gtt aat taa ccc ggg gat ccg tcg acc TTT GTA TAG TTC ATC CAT GCC-3'). The vYFP fragment was inserted into the pBS NheI-SEC15(HindIII-BclI) at the NheI site to generate pBS vYFP-SEC15.
The HindIII-BclI fragment was subcloned from pBS SEC15-vYFP C into pRS415 SEC15
at HindIII and BclI sites. To express a fusion of GST-mouse myosin Va globular tail domain (1,444-1,853 a.a.), the myosin Va fragment was amplified using primers, (5'-AGT gga tcc GGG CAG ATG GAG AAC ATA TCT C-3') and (5'-TCG ctc gag TCA GAC CCG TGC GAT GAA G-3'). The myosin Va fragment was inserted into pGEX4T-1 at BamHI and XhoI sites to generate pGEX4T-1 mMyosin Va-GTD.
GST pull down assay
GST and all GST fusion proteins were expressed in E. coli BL21 DE3 star. Expression was induced by 0.2 mM IPTG at 16°C; over-night. Cells were lysed in PBS [pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO4, 2 mM KH 2 PO 4 , 1 mM DTT]. Lysates were incubated with glutathione sepharose beads (GE Healthcare). Yeast cells grown in YEPD medium were lysed with glass beads in pull-down buffer [20 mM Hepes-KOH (pH7.5), 100 mM KCl, 1 mM EDTA, 10 % glycerol, 1x Sigma yeast protease inhibitor cocktail, 20 mM sodium pyrophosphate, 10 mM NaN 3 , 20 mM NaF, 1 mM sodium orthovandate, 100 mM -glycerophosphate]. Lysates were solubilized with 0.5% octyl-glucoside and incubated with glutathione beads bound with GST or GST fusion protein which were prewashed with pull-down buffer including 1 mg/ml BSA. Beads were washed with pulldown buffer with BSA once, and with pull-down buffer without BSA four times. Proteins were analyzed by SDS-PAGE, CBB staining and immunoblot.
His-tagged Myo2 cargo-binding domain was expressed in E. coli BL21 DE3 star.
Expression was induced by 0.2 mM IPTG; 16°C, over-night. Cells were lysed in PBS.
The lysates were bound to Ni-NTA agarose beads (QIAGEN). Beads were washed with PBS and eluted with 100 mM imidazole. Eluted proteins were dialyzed in PBS. GST or GST-Sec4 bound beads were washed with preloading buffer [20 mM Hepes-KOH (pH7.5), 100 mM KCl, 1 mM EDTA, 5 mM MgCl 2 , 1mM DTT, 10 % glycerol, 1 mg/ml BSA] and preloaded with 10 mM GDP or GTP S at room temperature for 45 min. MgCl 2 concentration was adjusted to 10 mM, and incubation was continued for another 15 min. To prepare NIH 3T-3 cell extracts, NIH 3T-3 cells were washed with ice cold PBS and lysed with lysis buffer [20 mM Hepes-KOH (pH7.5), 100 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1 % Triton X-100, 10 % glycerol, 1x Sigma yeast protease inhibitor cocktail, 20 mM sodium pyrophosphate, 10 mM NaN 3 , 20 mM NaF, 1 mM sodium orthovandate, 100 mM -glycerophosphate] by sonication. A high speed supernatant (S100) was prepared from a low speed supernatant (S13) by centrifugation, 100,000 x g, 1 hr. GST or GSTmMyosin Va-GTD bound beads were washed with lysis buffer with 1 mg/ml BSA. GST bound beads were incubated with the solubilized S100 at 0°C for 1.5 h in lysis buffer with BSA. Beads were washed with lysis buffer with BSA once, and with lysis buffer without BSA four times. Proteins were analyzed by SDS-PAGE, CBB staining and immunoblot.
Random Mutagenesis of MYO2
To obtain a second site mutation that suppressed the lethality of myo2-Y1415R, the myo2-Y1415R tail region from pRS426 myo2-Y1415R was PCR amplified with Taq polymerase. Primers used were MYOL (5'-CGG AGA CTT GCA AAA CG-3') and MYOR (5'-TGT GGA ATT GTG AGC GG-3') (Catlett et al., 2000) . pRS413 myo2-Y1415R was linearized with EcoRI and phosphatase treated. Linearized pRS413 myo2-Y1415R was cotransformed with the PCR-amplified myo2-Y1415R tail into myo2D cells containing YCp50 MYO2 (LWY2947). Transformants were replica plated onto 5-FOA containing media to remove YCp50 MYO2. Plasmids were isolated from viable colonies on the 5-FOA containing media and retransformed into LWY2947 to confirm that the new mutations enabled yeast viability.
Western Blot Analysis
SDS-PAGE and Western blot analysis were performed using standard procedures.
Primary and secondary antibodies were used at the following concentrations: affinitypurified goat anti-Myo2 cargo-binding domain (1:3,000), HRP-donkey anti-goat IgG
(1:5,000; Jackson ImmunoResearch Laboratories), mouse anti-GFP (1:5000; Roche), HRP-goat anti-mouse IgG (1:5,000; Jackson ImmunoResearch Laboratories), mouse antiPgk1 (1:20,000; Invitrogen), HRP-goat anti-mouse IgG (1:20,000; Jackson ImmunoResearch Laboratories), rabbit anti-Sec6p (1:4,000), rabbit anti-Sec15 (1:4,000), rabbit anti-Exo84 (1:4,000), HRP-goat anti-rabbit IgG (1:10,000; Jackson
ImmunoResearch Laboratories), HRP activity was detected using ECL plus (Amersham Bioscience).
Surface Plasmon Resonance (SPR)
The cDNA corresponding to cargo-binding domain (CBD) of Myo2 (1131 Myo2 ( -1574 was cloned into expression vector pNIC28-BSA4 (Gen Bank Accession No. EF198106 (Stols et al., 2002) . Sec4 buffers were supplemented with 5 mM MgCl 2 throughout purification. Cells were disrupted by sonication and the bacterial lysate was centrifuged at 20,000g for 30 min.
The supernatant was passed through a 0.2 m filter, and loaded onto Ni 2+ -agarose (Chromatrin) or amylose resin (New England Biolabs). Column were washed with 10
